KAMAU THERAPEUTICS Trademark

Trademark Overview


On Friday, August 11, 2023, a trademark application was filed for KAMAU THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the KAMAU THERAPEUTICS trademark a serial number of 98128117. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Friday, July 5, 2024. This trademark is owned by Kamau Therapeutics, Inc.. The KAMAU THERAPEUTICS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations in the nature of genetically modified cells for use in the treatment of genetic diseases and disorders; pharmaceutical preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for gene therapy, gene editing, genome editing, and targeted gene replacement and insertion; cell therapy products in the nature of genetically modified cells for the treatment of genetic diseases and disorders; gene therapy products in the nature of genetically engineered human genes for the treatment of genetic diseases and disorders; pharmaceutical preparations for non-genotoxic conditioning to enable engraftment; pharmaceutical preparations containing templates of DNA sequences to restore and normalize the function in a disease-causing gene; gene edited and corrected human cells for medical use

Pharmaceutical research and development services; Research in the fields of pharmaceuticals, gene regulation, gene modification, gene correction, cell therapy, gene therapy, genetic diseases and disorders, and templates containing DNA sequences, and targeted gene replacement and insertion; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; research and development of therapeutics pharmaceuticals using gene editing; providing medical and scientific research information in the field of pharmaceuticals, gene regulation, gene modification, gene correction, cell therapy, gene therapy, genetic diseases and disorders, and templates containing DNA sequences, and targeted gene replacement and insertion; research in the field of clustered regularly interspaced short palindromic repeats (CRISPR) and homology directed repair (HDR) technologies
kamau therapeutics

General Information


Serial Number98128117
Word MarkKAMAU THERAPEUTICS
Filing DateFriday, August 11, 2023
Status680 - APPROVED FOR PUBLICATION
Status DateFriday, July 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations in the nature of genetically modified cells for use in the treatment of genetic diseases and disorders; pharmaceutical preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for gene therapy, gene editing, genome editing, and targeted gene replacement and insertion; cell therapy products in the nature of genetically modified cells for the treatment of genetic diseases and disorders; gene therapy products in the nature of genetically engineered human genes for the treatment of genetic diseases and disorders; pharmaceutical preparations for non-genotoxic conditioning to enable engraftment; pharmaceutical preparations containing templates of DNA sequences to restore and normalize the function in a disease-causing gene; gene edited and corrected human cells for medical use
NOT AVAILABLETHERAPEUTICS
Goods and ServicesPharmaceutical research and development services; Research in the fields of pharmaceuticals, gene regulation, gene modification, gene correction, cell therapy, gene therapy, genetic diseases and disorders, and templates containing DNA sequences, and targeted gene replacement and insertion; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; research and development of therapeutics pharmaceuticals using gene editing; providing medical and scientific research information in the field of pharmaceuticals, gene regulation, gene modification, gene correction, cell therapy, gene therapy, genetic diseases and disorders, and templates containing DNA sequences, and targeted gene replacement and insertion; research in the field of clustered regularly interspaced short palindromic repeats (CRISPR) and homology directed repair (HDR) technologies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 11, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, September 11, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKamau Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events


Event DateEvent Description
Tuesday, August 15, 2023NEW APPLICATION ENTERED
Monday, September 11, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 21, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 21, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 21, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, April 12, 2024ASSIGNED TO EXAMINER
Wednesday, April 17, 2024NON-FINAL ACTION WRITTEN
Wednesday, April 17, 2024NON-FINAL ACTION E-MAILED
Wednesday, April 17, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 26, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, June 26, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, June 26, 2024EXAMINERS AMENDMENT -WRITTEN
Friday, July 5, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 26, 2024EXAMINER'S AMENDMENT ENTERED